ABSTRACT
BACKGROUND: Bariatric surgery is a successful method for weight loss in cases of morbid obesity; however, as an invasive procedure, surgical complications may occur. Low-level laser therapy (LLLT) has been increasingly used due to its effectiveness in controlling the inflammatory response, accelerating tissue repair, and reducing pain. The objective of this study was to investigate photobiomodulation effects after bariatric surgery and determine the laser actions during the inflammatory process, wound healing (clinical observation), and analgesia. METHODS: This study was a randomized, placebo-controlled, clinical trial in which 85 patients underwent Roux en-Y gastric bypass (RYGB) by conventional techniques (i.e., open surgery). Patients were divided into two groups and were irradiated with LLLT at 10 different points through the surgical scar in three sessions of applications: the laser group (laser-on) consisted of 43 patients who received the CW diode laser (MMOptics), while the placebo group (laser-off) consisted of 42 patients who were treated by the same protocol but with a disabled laser. Temperature was measured by a digital thermometer in both groups, and pain was evaluated using the visual analogue scale for pain. Biochemical analysis and digital images were used to document and evaluate the inflammatory response as well as tissue repair process at the surgical wound site. RESULTS: Patients in the laser group demonstrated diminished wound temperature as erythrocyte sedimentation rate (ESR) compared with the placebo group, indicating better inflammatory process control as well as improved wound healing and reduced pain. CONCLUSIONS: LLLT applied with the described protocol led to a decrease by biochemical markers and wound temperature compared with the placebo, which indicated that LLLT was able to control the inflammatory process; in addition, seroma and pain were reduced and cicatrization was improved by this preventive procedure.
Subject(s)
Gastric Bypass/methods , Low-Level Light Therapy/methods , Obesity, Morbid/surgery , Surgical Wound/radiotherapy , Wound Healing/radiation effects , Adult , Body Mass Index , Cicatrix/prevention & control , Female , Humans , Lasers, Semiconductor , Male , Middle Aged , Obesity, Morbid/diagnosis , Pain, Postoperative/prevention & control , Postoperative Care/methods , Reference Values , Treatment Outcome , Wound Healing/physiologyABSTRACT
Foram estudadas as alteraçöes histológicas do endométrio causadas em 30 mulheres por injeçäo intramuscular única da associaçäo de 150 mg de acetofenido de didroxiprogesterona com 10 mg de enantato de estradiol. O uso dessa associaçäo hormonal causou assincronismo na evoluçäo dos parâmetros endometriais, interferiu nos índices cíclicos do muco cervical e foi eficaz na supressäo da ovulaçäo. O fármaco teve açäo predominantemente periférica no endométrio, porém näo causou reaçöes adversas nem sugestivas de malignidade nas mulheres que o usaram
Subject(s)
Adult , Humans , Female , Algestone Acetophenide/administration & dosage , Endometrium/drug effects , Estradiol/administration & dosage , Injections, IntramuscularABSTRACT
Foram estudadas as alteraçöes histológicas do endométrio causadas por injeçäo intramuscular única da associaçäo de 150 mg de acetofenido de diidroxiprogesterona com 10 mg de enantato de estriol, em 30 mulheres. O uso dessa associaçäo hormonal causou assincronismo na evoluçäo dos parâmetros endometriais, interferiu nos índices cíclicos do muco cervical e foi eficaz na supressäo da ovulaçäo. O fármaco teve açäo predominantemente periférica no endométrico, porém näo causou reaçöes adversas nem sugestivas de malignidade nas mulheres que o usaram
Subject(s)
Adult , Humans , Female , Contraceptive Agents, Female/pharmacology , Endometrium/drug effects , Algestone Acetophenide , EstradiolABSTRACT
Realizou-se um ensaio em 15 usuárias da Unidade de Planejamento Familiar de Säo Paulo, com o propósito de estudar o efeito anticonceptivo e as açöes endócrinas de uma injeçäo mensal do contraceptivo acetofenido de dihidroxiprogesterona 150 mg associado a 10 mg de enantato de estradiol. As variaçöes encontradas a nível hormonal, tanto de estrogênio como de progesterona, confirmam que o fármaco apresenta um excelente efeito anovulatório. Os efeitos adversos foram mínimos e, em relaçäo ao padräo menstrual, näo se encontrou diferenças significativas. Considerou-se esta terapêutica como de grande segurança, praticidade e tolerância, quando se utiliza com fins anticonceptivos
